ASH 2019 Treatment of Older FCR Ineligible CLL Pts: 5 Years Follow‐up on Ibrutinib, Time Limited Therapies & High Rates of Undetectable MRD With Ibrutinib/Venetoclax

13 views
March 20, 2020
0 Comments
Login to view comments. Click here to Login
Annual Updates from ASH 2019